Literature DB >> 23872830

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

J M Rae1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23872830     DOI： 10.1038/clpt.2013.102

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  9 in total

1.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

Authors:  Sam Mostafa; Carl M J Kirkpatrick; Keith Byron; Leslie Sheffield
Journal:  J Neural Transm (Vienna)       Date:  2018-09-06       Impact factor: 3.575

2.  CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer.

Authors:  Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

3.  Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  Matthew P Goetz; Hiltrud Brauch; Mark J Ratain; Nancy J Cox; Yusuke Nakamura; Richard Weinshilboum; James N Ingle
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

4.  Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population.

Authors:  Lei Lei; Xian Wang; Xiao-Dan Wu; Zeng Wang; Zhan-Hong Chen; Ya-Bin Zheng; Xiao-Jia Wang
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

5.  Genomic medicine, precision medicine, personalized medicine: what's in a name?

Authors:  D M Roden; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2013-08       Impact factor: 6.875

Review 6.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

7.  The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.

Authors:  Jeanine Marie Nardin; Werner Schroth; Thais Abreu Almeida; Thomas Mürdter; Solane Picolotto; Evelyn Castillo Lima Vendramini; Reiner Hoppe; Jenifer Primon Kogin; Diandra Miqueleto; Silvia Dark Robaskievicz de Moraes; Matthias Schwab; Roberto Flavio Pecoits-Filho; Hiltrud Brauch; José Claudio Casali-da-Rocha
Journal:  Clin Transl Sci       Date:  2019-11-09       Impact factor: 4.689

8.  Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

Authors:  P Saladores; T Mürdter; D Eccles; B Chowbay; N K Zgheib; S Winter; B Ganchev; B Eccles; S Gerty; A Tfayli; J S L Lim; Y S Yap; R C H Ng; N S Wong; R Dent; M Z Habbal; E Schaeffeler; M Eichelbaum; W Schroth; M Schwab; H Brauch
Journal:  Pharmacogenomics J       Date:  2014-08-05       Impact factor: 3.550

9.  Clinical Application of Pharmacogenetics: Where are We Now?

Authors:  Ron Hn van Schaik
Journal:  EJIFCC       Date:  2013-02-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.